OPKO Health, Inc. (NASDAQ:OPK) Receives Average Recommendation of “Hold” from Brokerages

OPKO Health, Inc. (NASDAQ:OPK) has earned an average rating of “Hold” from the six research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $1.55.

Several equities research analysts recently weighed in on the company. Wall Street Zen lowered OPKO Health from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings upgraded OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Finally, Barrington Research cut OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OPK. Caprock Group LLC purchased a new position in OPKO Health during the third quarter valued at $26,000. Zacks Investment Management purchased a new position in OPKO Health during the fourth quarter valued at $27,000. StoneX Group Inc. purchased a new position in OPKO Health during the fourth quarter valued at $27,000. Swiss Life Asset Management Ltd purchased a new position in OPKO Health during the third quarter valued at $30,000. Finally, Savant Capital LLC purchased a new position in shares of OPKO Health in the third quarter worth $33,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.46 on Friday. The company has a quick ratio of 3.17, a current ratio of 3.61 and a debt-to-equity ratio of 0.28. OPKO Health has a twelve month low of $0.98 and a twelve month high of $1.60. The firm has a market capitalization of $1.10 billion, a PE ratio of -5.41 and a beta of 1.50. The stock’s 50 day moving average is $1.21 and its 200 day moving average is $1.25.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The company had revenue of $124.20 million for the quarter, compared to analyst estimates of $130.51 million. During the same period in the previous year, the company posted ($0.10) earnings per share. The firm’s revenue was down 17.1% on a year-over-year basis. Research analysts forecast that OPKO Health will post -0.29 earnings per share for the current fiscal year.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.